Gonzalo Suárez

Prof. Dr. Gonzalo Suárez

orcid
Pharmacology and Therapeutic Veterinary

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Veterinary Parasitology
Verified
Journal Article
Closed access
VBVirginie Barrère
Virginie Barrère
LALuis Alvarez
Luis Alvarez
GSGonzalo Suárez
Gonzalo Suárez
LCLaura Ceballos
Laura Ceballos
LMLaura Moreno
Laura Moreno
RPRoger K. Prichard
Roger K. Prichard

17 March 2019 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
GRGastón Risi
Gastón Risi
EAElena Aguilera
Elena Aguilera
ELEnrique Ladós
Enrique Ladós
GSGonzalo Suárez
Gonzalo Suárez
ICInés Carrera
Inés Carrera
GSGustavo Salinas
Gustavo Salinas
Nematode parasites have a profound impact on humankind, infecting nearly one-quarter of the world’s population, as well as livestock. There is a pressing need for discovering nematicides due to the spread of resistance to currently used drugs. The free-living nematode Caenorhabditis elegans is a formidable experimentally tractable model organism that offers key advantages in accelerating nematicide discovery. We report the screening of drug-like libraries using an overnight high-throughput C. elegans assay, based on an automated infrared motility reader. As a proof of concept, we screened the “Pathogen Box” library, and identical results to a previous screen using Haemonchus contortus were obtained. We then screened an in-house library containing a diversity of compound families. Most active compounds had a conjugation of an unsaturation with an electronegative atom (N, O, or S) and an aromatic ring. Importantly, we identified symmetric arylidene ketones and aryl hydrazine derivatives as novel nematicides. Furthermore, one of these compounds, (1E,2E)-1,2-bis(thiophen-3-ylmethylene)hydrazine, was active as a nematicide at 25 µm, but innocuous to the vertebrate model zebrafish at 50 µm. Our results identified novel nematicidal scaffolds and illustrate the value of C. elegans in accelerating nematicide discovery using a nonlabor-intensive automated assay that provides a simple overnight readout.


1 June 2003 in Theriogenology
Verified
Journal Article
Closed access
RURodolfo Ungerfeld
Rodolfo Ungerfeld
GSGonzalo Suárez
Gonzalo Suárez
BCBettina Carbajal
Bettina Carbajal
LSLeticia Silva
Leticia Silva
MLMariana Laca
Mariana Laca
EREdgardo Rubianes
Edgardo Rubianes

1 May 2015 in Veterinary Parasitology
Verified
Journal Article
Open access
LALuis Alvarez
Luis Alvarez
GSGonzalo Suárez
Gonzalo Suárez
LCLaura Ceballos
Laura Ceballos
LTLaura Moreno Torrejon
Laura Moreno Torrejon
CCCandela Canton
Candela Canton
CLCarlos Lanusse
Carlos Lanusse
The main goals of the current work were: (a) to assess the ivermectin (IVM) systemic exposure and plasma disposition kinetics after its administration at the recommended dose, x5 and x10 doses to lambs, (b) to compare the clinical efficacy of the same IVM dosages in lambs infected with an IVM-resistant isolate of Haemonchus contortus, and (c) to assess the expression of the transporter protein P-glycoprotein (P-gp) in H. contortus recovered at 14 days after administration of the IVM dose regimens. There were two separated trials where IVM was administered either subcutaneously (SC, Experiment I) or intraruminally (IR, Experiment II). Each experiment involved twenty-four (24) lambs artificially infected with a highly resistant H. contortus isolate. Animals were allocated into 4 groups (n=6) and treated with IVM at either 0.2 (IVM x1), 1 (IVM x5) or 2mg/kg (IVM x10). Plasma samples were collected up to 12 days post-treatment and analysed by HPLC. An untreated-control Group was included to assess the comparative anthelmintic efficacy of the different treatments. The level of expression of Pgp in H. contortus specimens obtained from lambs both untreated and IR treated with the different IVM doses was quantified by real time PCR. Parametric and non-parametric tests were used to compare the statistical significance of the results (P<0.05). After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL. Dose-adjusted AUC0-LOQ and Cmax were similar among doses, demonstrating dose proportionality for IVM after both SC and IR administration at the three different doses. The efficacies against resistant H. contortus after the SC treatment were 42% (IVM SC1), 75% (IVM SCx5) and 75% (IVM SCx10). However, the IR IVM treatment reached clinical efficacies ranging from 48% (IVM IRx1) up to 96% (IVM IRx5) and 98% (IVM IRx10). None of the IR IVM treatments increased the expression of P-gp in adult H. contortus at 14 days post-treatment compared to samples collected from the untreated control group. An enhanced parasite exposure of the drug at the abomasum may explain the improved efficacy against this recalcitrant H. contortus isolate observed only after the IR administration at 5- and 10-fold the IVM therapeutic dosage.

1 March 2014 in Veterinary Parasitology
Verified
Journal Article
Closed access
GSGonzalo Suárez
Gonzalo Suárez
LALuis Alvarez
Luis Alvarez
DCDaniel Castells
Daniel Castells
LMLaura Moreno
Laura Moreno
PFPietro Fagiolino
Pietro Fagiolino
CLCarlos Lanusse
Carlos Lanusse